Tukysa (tucatinib)

Numéro de dossier de l’APP: 21661
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination
Promoteur/fabricant:
Seagen Canada Inc.
Numéro de projet de l’ACMTS:
PC0243
Lettre-contrat de l’APP:
Conclusion du processus de négociation: